Differential Diagnosis and Management of Elevated Transaminases, Leukocytosis, and Thrombocytopenia

Etiology and Diagnosis

The European Society of Medical Oncology suggests that chemotherapy-induced hepatotoxicity is a leading cause of elevated transaminases in cancer patients, particularly those with ovarian cancer, with a prevalence of 31% in patients with hepatic involvement 2, 4
The American College of Gastroenterology recommends that liver metastases from ovarian cancer should be considered as a potential cause of transaminase elevation, although this occurs in less than 5% of cases with ALT ≥3× ULN 2
The American Heart Association notes that amiodarone hepatotoxicity is possible but typically causes a mixed or cholestatic pattern rather than isolated transaminase elevation, and usually develops after months of therapy 5
The European Society of Cardiology states that Eliquis (apixaban) does not cause thrombocytopenia, as anticoagulants affect clotting factors, not platelet production or destruction 1, 7

The American College of Gastroenterology recommends repeating comprehensive liver panel including ALT, AST, alkaline phosphatase, total and direct bilirubin, albumin, and INR to assess for Hy's Law criteria, which signals severe drug-induced liver injury 8, 9
The European Society of Medical Oncology suggests checking creatine kinase to exclude muscle injury as a source of transaminase elevation, particularly given hypoxic respiratory failure and potential immobility 9
The American Society of Hematology recommends obtaining complete blood count with differential to characterize the leukocytosis pattern and quantify thrombocytopenia severity 10

The European Society of Medical Oncology recommends holding or reducing chemotherapy dose until transaminases trend downward, as ALT >3× ULN typically requires dose modification 4, 8
The American College of Cardiology suggests that if platelets are between 25,000-50,000/μL, anticoagulation should be held temporarily, and chemotherapy dose intensity should be reduced or delayed 1
The American Society of Hematology recommends platelet transfusion if platelets are less than 10,000/μL for prophylaxis or less than 50,000/μL if bleeding or invasive procedure is planned 1
The European Respiratory Society recommends treating underlying rhinovirus bronchiolitis with supportive care, CPAP optimization, and antibiotics only if bacterial superinfection is confirmed 3
The American College of Gastroenterology suggests monitoring for tumor lysis syndrome if leukocytosis is from CLL progression, by checking LDH, uric acid, phosphate, and calcium 10